Attorney General Actions and Climate Crimes Accountability Fund (Climate Crimes Accountability Act)
HB 572 would change Maryland law governing opioid overdose reversal drugs, such as naloxone, when they are provided under a standing order. The bill requires a licensed health care provider issuing a standing order to allow the individual receiving the drug to choose any formulation of any FDA-approved opioid overdose reversal drug. In practical terms, that means a person could select among approved products and delivery forms rather than being limited to one option chosen by the provider or dispensing entity.
The bill also adds a new provision stating that an authorized private or public entity that prescribes and dispenses opioid overdose reversal drugs cannot be required to keep in stock or dispense every FDA-approved formulation. This appears intended to prevent an operational mandate that would force providers, clinics, or community organizations to carry the full range of products. The bill takes effect October 1, 2025, and amends the Health – General Article provisions governing standing orders, written agreements, and dispensing authority for overdose reversal medications.
HB 572 would amend Maryland’s Health – General Article, specifically the subtitle governing opioid overdose reversal drugs, by changing how standing orders are implemented and by adding a new limitation on stocking and dispensing requirements. It would affect licensed health care providers, pharmacists, local health departments, community-based organizations, substance use treatment organizations, and other authorized public or private entities involved in naloxone or similar overdose-reversal distribution. The bill preserves existing authority to prescribe and dispense these drugs while clarifying patient choice and reducing potential inventory obligations for dispensing entities.
Based on the bill text and the limited available context, the measure appears to be framed as a practical public health bill rather than a controversial policy change. Its stated purpose suggests support for broader access and consumer choice in overdose reversal medications, while also addressing provider flexibility. No committee transcript or vote record is available here, so there is no documented floor or committee sentiment beyond the bill’s structure and sponsor intent.
The main point of potential contention is the balance between individual choice and operational burden. Supporters are likely to favor the requirement that individuals be allowed to choose any FDA-approved formulation, arguing it improves access and respects patient preference. Entities that prescribe or dispense these drugs may favor the companion protection from being required to stock or dispense every formulation, since that limits cost and inventory burdens. Any disagreement would likely center on whether the bill goes far enough to ensure access to all formulations or whether it appropriately avoids imposing unfunded or impractical stocking mandates on providers and community organizations.